Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Quanta Services Inc (PWR) Price & Performance

Gilead Sciences, Inc.Trade
Quanta Services IncTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Quanta Services Inc — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $168.35B), while Quanta Services Inc trades at $687.94 (market cap $100.82B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.

GILDPWR
Market Cap
$168.35B$100.82B
Sector
HealthIndustrials
52-Week High
$155.80$785.24
52-Week Low
$110.56$372.50
Enterprise Value
$191.42B$106.91B
Dividend Yield
2.42%0.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.

The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.

Quanta Services Inc

PWR trades at $660.86, down 1.64% over 24 hours, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.24 versus $3.31 expected, and raised its full-year 2026 outlook. Revenue growth is robust, reaching $28.48B in 2025, though valuation ratios like a P/E of 76.73 appear elevated. Analyst sentiment is overwhelmingly positive, with 26 buy ratings and a consensus price target of $809.75.

The outlook for PWR is bullish, driven by record backlog and infrastructure demand, but high valuation and negative net cash flow pose risks. Investors face a trade-off between strong growth prospects and premium pricing, with execution on raised guidance being critical for further upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Quanta Services Inc

Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.

Read more on PWR